Last reviewed · How we verify
Aragon Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
1 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| ADT (Standard of Care) | ADT (Standard of Care) | phase 3 | Hormonal therapy / Androgen deprivation | Androgen receptor / GnRH receptor (depending on specific ADT agent) | Oncology |
Therapeutic area mix
- Oncology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Arvinas Androgen Receptor, Inc. · 1 shared drug class
- Astellas Pharma · 1 shared drug class
- AstraZeneca · 1 shared drug class
- City of Hope Medical Center · 1 shared drug class
- Pfizer Inc. · 1 shared drug class
- Tata Memorial Centre · 1 shared drug class
- Triple Hair Inc · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Aragon Pharmaceuticals, Inc.:
- Aragon Pharmaceuticals, Inc. pipeline updates — RSS
- Aragon Pharmaceuticals, Inc. pipeline updates — Atom
- Aragon Pharmaceuticals, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Aragon Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aragon-pharmaceuticals-inc. Accessed 2026-05-17.